20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Spyre Therapeutics Inc. (SYRE) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 125 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, SYRE reported $0M in revenue and ($155M) in net income.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $90M | $0M | $1M | $1M | $2M | $19M | $0M | $0M | $4M | $5M | $5M | $6M | — |
| Gross Profit | — | ($172M) | $1M | $0M | $2M | $19M | ($2M) | ($1M) | $4M | $5M | $5M | $6M | $0M |
| Gross Margin % | — | — | 100.0% | -8.8% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 98.5% | — |
| Operating Income (EBIT) | ($202M) | ($210M) | ($209M) | ($242M) | ($85M) | ($66M) | ($81M) | ($80M) | ($45M) | ($28M) | ($22M) | ($11M) | ($9M) |
| Operating Margin % | -222.8% | — | -23540.2% | -27348.0% | -3640.2% | -350.3% | — | — | -1169.3% | -531.7% | -473.3% | -185.9% | — |
| Net Income | ($179M) | ($155M) | ($208M) | ($339M) | ($84M) | ($66M) | ($81M) | ($78M) | ($44M) | ($27M) | ($22M) | ($11M) | ($10M) |
| Net Margin % | -198.3% | — | -23478.3% | -38238.2% | -3598.7% | -351.1% | — | — | -1140.6% | -523.3% | -468.8% | -185.6% | — |
| EBITDA | ($201M) | ($210M) | ($208M) | ($242M) | ($82M) | ($64M) | ($79M) | ($77M) | ($45M) | ($27M) | ($22M) | ($11M) | ($10M) |
| Earnings Per Share (EPS) | $-0.52 | $-3.30 | $-4.42 | $-49.12 | $-24.86 | $-25.02 | $-37.89 | $-61.23 | $-53.25 | $-27.00 | $-55.40 | $-24.71 | $-10.00 |
| Shares Outstanding (M) | 346M | — | 47M | 7M | 3M | 3M | 2M | 1M | 1M | 1M | 0M | 0M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $90M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $45M | ($45M) | — | — | — | — | — |
| Gross Margin % | — | — | 50.0% | — | — | — | — | — | — |
| Operating Income (EBIT) | — | ($46M) | ($57M) | ($57M) | ($42M) | ($54M) | ($61M) | ($55M) | ($44M) |
| Operating Margin % | — | — | -63.2% | — | — | — | — | — | — |
| Net Income | ($36M) | ($69M) | ($63M) | ($11M) | ($37M) | ($45M) | ($56M) | ($69M) | ($39M) |
| Net Margin % | — | — | -69.1% | — | — | — | — | — | — |
| EBITDA | — | ($76M) | ($63M) | ($11M) | ($52M) | ($45M) | ($56M) | ($69M) | ($39M) |
| Earnings Per Share (EPS) | — | $-0.20 | $-1.05 | $-0.19 | $-0.60 | $-0.74 | $-1.20 | $-1.36 | $-0.86 |
| Shares Outstanding (M) | — | 346M | — | 60M | 61M | 60M | 47M | 51M | 45M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($186M) | ($169M) | ($157M) | ($100M) | ($80M) | ($54M) | ($76M) | ($66M) | ($32M) | ($25M) | ($19M) | ($11M) | ($7M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $1M | $4M | $1M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($186M) | ($169M) | ($157M) | ($100M) | ($80M) | ($54M) | ($80M) | ($67M) | ($33M) | ($25M) | ($19M) | ($11M) | ($8M) |
| FCF Margin % | -205.3% | — | -17766.4% | -11276.5% | -3442.8% | -289.7% | — | — | -838.9% | -484.8% | -411.7% | -183.9% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($70M) | ($58M) | ($45M) | ($37M) | ($47M) | ($41M) | ($37M) | ($29M) | ($62M) |
| Free Cash Flow (FCF) | ($70M) | ($58M) | ($45M) | ($37M) | ($47M) | ($41M) | ($37M) | ($29M) | ($62M) |
| FCF Margin % | — | — | -49.3% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B | $778M | $608M | $342M | $71M | $110M | $162M | $83M | $78M | $56M | $67M | $39M | $3M | $5M |
| Cash & Cash Equivalents | $162M | $86M | $89M | $189M | $35M | $15M | $90M | $19M | $22M | $13M | $48M | $29M | $3M | $5M |
| Total Liabilities | $72M | $63M | $91M | $158M | $21M | $26M | $22M | $23M | $10M | $6M | $4M | $3M | $1M | $1M |
| Total Debt (Short + Long-Term) | — | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $1.1B | $715M | $518M | $184M | $50M | $84M | $140M | $60M | $67M | $50M | $63M | $36M | $2M | $3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYRE viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms